Protein Expression and Codon 72 Polymorphism of TP53 Gene in Triple Negative Breast Cancer

• Autor(a) principal: Lopes,Leandra Fiori
• Data de Publicação: 2014
• Outros Autores: Guembarovski,Roberta Losi, Guembarovski,Alda Losi, Kishima,Marina Okuyama, Campos,Clodoaldo Zago, Derossi,Daniela Rudgeri, Ariza,Carolina Batista, Ozawa,Patricia Midori Murobushi, Oliveira,Carlos Eduardo Coral de, Banin-Hirata,Bruna Karina, Vitiello,Glauco Akelinghton Freire, Borelli,Sueli Donizete, Watanabe,Maria Angelica Ehara
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Brazilian Archives of Biology and Technology
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-89132014000600895
• topic: breast cancer; TNBC; TP53; genetic polymorphism; immunohistochemistry

A subgroup of tumor that has received attention is triple-negative breast cancer (TNBC), which presents phenotype of negative estrogen receptor, negative progesterone receptor and has no overexpression of HER2. TP53 acts as a tumor suppressor limiting the proliferation of damaged cells. A polymorphic site (rs1042522) of TP53 encodes either an arginine or a proline amino acid, but its biological significance remains unclear. This study aimed to investigate this variant and its expression in search for a possible involvement in TNBC susceptibility and clinical outcome. Genetic polymorphism was evaluated in 50 patients and 115 controls by PCR based methodology and immunohistochemistry was done with monoclonal antibody. Case-control study showed no positive or negative association (OR= 0.95; CI95%= 0.48-1.89). Comparison of genotypes and clinical outcome showed no significant results. Despite most of patients presented p53 positive staining by immunohistochemistry, there was no significant association in relation to prognostic parameters. Results demonstrated a lack of association between codon 72 polymorphism, susceptibility and prognosis of TNBC. Immunohistochemistry analysis should be done more carefully, since most of the patients had the somatic mutation of p53, which could be an indicator of prognostic value in TNBC.